4:17 PM
 | 
Apr 26, 2019
 |  BC Extra  |  Clinical News

Patient access pitfalls, regulatory inconsistencies hamper tissue agnostic drugs

At a Friday meeting FDA co-hosted with ASCO and Friends of Cancer Research, patient advocates expressed concern over their ability to access newly approved tissue-agnostic medicines, as well as clinical trials assessing up-and-coming treatments based on molecular markers rather than tissue of origin. Stakeholders also raised concerns about the lack of access to tumor-profiling technologies and inconsistent approaches among regulators to tissue-agnostic drug development.

At the workshop on the development of therapies for tissue agnostic, biomarker-based indications, patients talked about the difficulty of finding studies enrolling patients based on mutations and/or tumor molecular markers rather than tumor type.

Ann Ramer, a patient advocate with family members who harbor p53 mutations, cited challenges in searching ClinicalTrials.gov by tumor type or for rare...

Read the full 582 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >